D-α-Hydroxyglutaric acid

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway:	HY-113038 13095-47-1 C _s H ₈ O _s 148.11 Reactive Oxygen Species; ATP Synthase; mTOR; Endogenous Metabolite Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Membrane Transporter/Ion Channel; PI3K/Akt/mTOR	HO HO HO HO HO HO HO HO HO HO HO HO HO H
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

SOLVENT & SOLUBILITY

	Mass Solvent Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutio	1 mM	6.7517 mL	33.7587 mL	67.5174 mL
	5 mM	1.3503 mL	6.7517 mL	13.5035 mL
	10 mM	0.6752 mL	3.3759 mL	6.7517 mL

BIOLOGICAL ACTIVITY		
Description	D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2- hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K _i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling ^{[1][2][3][4][5]} .	
IC ₅₀ & Target	Microbial Metabolite Human Endogenous Metabolite	
In Vitro	 D-α-Hydroxyglutaric acid ((R)-2-hydroxyglutarate) accumulates in human cancers carrying neomorphic mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes^{[1][2]}. A partial inhibition of KDM7A toward both H3K9me2 and H3K27me2 peptides is observed in the presence of 50 mM D-2-HG and 100 μM α-ketoglutarate (α-KG). Addition of 300 μM α-KG is capable of reversing the inhibition of Caenorhabditis elegans KDM7A (CeKDM7A) by 50 mM D-2-HG, indicating that D-2-HG is a weak competitive inhibitor against α-KG toward the CeKDM7A demethylase^[1]. D-α-Hydroxyglutaric acid is a weak inhibitor of TET hydroxylases. In the presence of 0.1 mM of α-KG, addition of 10 mM D-α-Hydroxyglutaric acid results in a partial (33%) inhibition of TET2 and addition of 50 mM D-α-Hydroxyglutaric acid results in more inhibition (83%) of TET2. D-α-Hydroxyglutaric acid exhibits a less pronounced inhibitory effect toward TET1^[1]. 	

Product Data Sheet



MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoD-α-Hydroxyglutaric acid strongly inhibits glucose utilization, CO2 production and the respiratory chain in rat cerebral cortex
and human skeletal muscle, as well as in submitochondrial particles from bovine heart, suggesting an impairment of the
aerobic metabolism^[5].
D-α-Hydroxyglutaric acid has also been proposed as an endogenous excitotoxic organic acid because it significantly
decreased cell viability in neuronal cultures from chick embryo telencephalons and from neonatal rat hippocampus through
stimulation of specific NMDA glutamate receptors^[5].
D-α-Hydroxyglutaric acid (0.01-1 mM) significantly increases chemiluminescence and thiobarbituric acid-reactive
substances (TBA-RS) and decreased total antioxidant reactivity (TAR) values in the cortical supernatants in 30-day-old-rats^[5].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• Biosensors (Basel). 2022 Jan 25;12(2):66.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Xu W, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011 Jan 18;19(1):17-30.

[2]. Fu X, et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab. 2015 Sep 1;22(3):508-15.

[3]. Martijn Kranendijk, et al. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis. 2012 Jul;35(4):571-87.

[4]. Martin Böttcher, et al. D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. Oncoimmunology. 2018 Mar 26;7(7):e1445454.

[5]. Alexandra Latini, et al. D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur J Neurosci. 2003 May;17(10):2017-22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA